ClinicalTrials.gg
CompletedNCT02103062Updated Apr 21, 2020Results posted

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

A Phase 2 interventional study of ABI-007 in Colorectal Neoplasms, sponsored by Celgene. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-21.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 3 of them phase 3. Colorectal Neoplasms · Bristol-Myers Squibb.

Enrollment
22nd of 27
41 · median 171
Started
2014
with 2 others
Phase 2
5 of 29
none open now
Registered
10th of 29
by date

Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 22nd largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2014, is one of 5 in phase 2, and was the 10th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of Abraxane (nab-paclitaxel) in subjects with previously treated metastatic colorectal cancer. Subjects will be placed into two separate cohorts based on their RAS mutation status.

Read the detailed description

ABI-007-COLO-001 is a Phase 2, single arm, open label, multicenter study to evaluate the efficacy and safety of Abraxane (nab-paclitaxel) given on days 1, 8 and 15 of a 28 day cycle in subjects with previously treated metastatic colorectal cancer. Subjects will be enrolled into cohorts by RAS mutation status (wildtype or mutated). Stage 1 in a given cohort will enroll 15 subjects in the Intention to Treat population and if more than 8 subjects have Progression Free Survival at the 8 week assessment, then Stage 2 will open in the respective cohort. Stage 2 will enroll an additional 28 subjects for a total of 43 subjects in each cohort. The study will be positive if more than 26 subjects with Progression Free Survival at the 8 week assessment are observed in 43 subjects per cohort. Interim analysis after Stage 1 did not meet protocol defined criteria to proceed to Stage 2. Patients currently enrolled will be followed for Progression Free Survival and until 28 days after last dose, secondary endpoints including overall survival will not be followed

03

Conditions studied

  • Colorectal Neoplasms

Keywords

  • Metastatic Colorectal Cancer
  • nab®Paclitaxel
  • Response Evaluation in Solid Tumors
  • Progression Free Survival
  • Overall Survival
  • Duration of Response
  • RAS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - 1. Subject is ≥ 18 years old at the time of signing the Form 2. Subject has histological or cytological diagnosis of adenocarcinoma of the colon or rectum, with evidence of 3. Subject has a known KRAS mutation status (mutated or wild-type). NRAS mutation status may be unknown. 4. Subject has documented disease progression ≤ 2 months after the last administration of the last standard therapy. a. Subjects treated with oxaliplatin in the setting, should have progressed during or within 6 months of completion of adjuvant therapy 5. Subject has either received prior treatment or was not a candidate for prior treatment, with fluoropyrimidine, oxaliplatin, irinotecan and an anti-VEGF therapy (e.g. bevacizumab or ziv-aflibercept); and if RAS wild-type tumors, an anti-EGFR therapy (e.g. cetuximab or panitumumab). 6. Subject has performance status 0 or 1 7. Subject has radiographically-documented , as per version 1.1 criteria 8. Subject has adequate organ functions, evidenced by the following: a. (SGOT), Alanine Transaminase (SGPT) ≤ 2.5 × , or \< 5 x upper limit of normal range if liver metastasis present b. Total ≤ 1.5 × upper limit of normal range c. Creatinine ≤ 1.5 × upper limit of normal range 9. Subject has adequate bone marrow function, evidenced by the following: a. ≥ 1.5 × 109 cells/millimeters3 b. ≥ 100 × 109 cells/millimeters3 (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample) c. ≥ 9 grams/decilitre (transfusion is permitted to fulfill this criterion) 10. Females of (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally for at least 24 consecutive months [i.e., has had menses at any time during the preceding 24 consecutive months]) must: a. Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective without interruption, 28 days prior to starting Product therapy (including dose interruptions), and for 3 months following the last dose of Investigational Product; and b. Have a negative serum pregnancy test (β -human Chorionic Gonadotrophin) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study therapy. This applies even if the subject practices true abstinence* from heterosexual contact. * True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Note: Periodic abstinence (e.g, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 11. Male subjects must practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following Investigational Product discontinuation, even if he has undergone a successful vasectomy. 12. Subject must understand and voluntarily sign an Informed Consent Form prior to any study related assessments or procedures being conducted. 13. Subject must be able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: - 1. Subject has current or a history of . In subjects who are symptomatic, a brain scan is required to exclude metastasis. 2. Subject has ≥ National Cancer Institute grade 2 peripheral neuropathy at screening 3. Subject has had prior treatment with regorafenib 4. Subject has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting Investigational Product, and/or from whom ≥ 30% of the bone marrow was irradiated. Radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed. 5. Subject has had major surgery within 14 days prior to starting Investigational Product or has not recovered from postoperative complications 6. Subject has not recovered from the acute toxic effects of prior anticancer therapy, radiation or major /significant trauma 7. Subject has a history of allergy or to nab-paclitaxel or any of the 8. Subject has a known history of the following within 6 months prior to enrollment (the decision to include the subject in the study): a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, Class III-IV heart failure, uncontrolled hypertension, cardiac dysrhythmia or abnormality, cerebrovascular accident, , or seizure disorder 9. Subject has a known infection with or C, or history of infection, or subject receiving or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications 10. Subject has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment 11. Subject has any other within 5 years prior to enrolment, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, or non-melanomatous skin cancer (all treatment of which should have been completed 6 months prior to enrollment) 12. Subject has a history of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa) 13. Subject has a history of interstitial lung disease , history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies 14. Subject has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate subject participation in the clinical study (e.g. chronic pancreatitis, chronic active hepatitis, etc.) 15. Subject is enrolled in any other clinical protocol or investigational study with an interventional agent or assessments that may interfere with study procedures 16. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study 17. Subject has any condition that confounds the ability to interpret data from the study 18. Subject is unwilling or unable to comply with study procedures 19. Subject is a pregnant or nursing female

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Abraxane (nab®paclitaxel)

    Abraxane (nab®paclitaxel) 125 milligrams per meter squared on days 1, 8 and 15 of a 28 day cycle

    Drug: ABI-007

Interventions

  • Also known as: Abraxane (nab®paclitaxel)

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Rate as Measured at Week 8

    PFS rate was measured by Investigator Assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 from the start of study treatment to disease progression or death from any cause, whichever occurred first.

    Time frame: At week 8 assessment period; up to 56 days

Secondary outcomes

  1. Percentage of Participants With Stable Disease for ≥ 8 Weeks, or Complete or Partial Response According to RECIST Version 1.1; Disease Control Rate (DCR)

    DCR was defined as the combined incidence of stable disease confirmed CR or PR and stable disease (SD) measured at the Week 8 assessment or later.

    Time frame: At week 8 and later; up to day 241

  2. Overall Survival

    Overall Survival was the time from the first dose of study drug to patient death from any cause.

    Time frame: Up to 241 days

  3. Overall Response Rate (ORR)

    ORR was defined as the combined incidence of Complete Response (CR) and Partial Response (PR), confirmed no less than 4 weeks after the criteria for response were first met based on RECIST 1.1. Tumor responses were assessed every 2 cycles using RECIST 1.1 and defined as: • Complete response-disappearance of all target lesions • Partial response- At least a 30% decrease in the sum of diameters of target lesions from baseline • Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD) • Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.

    Time frame: Up to 241 days

  4. Duration of Response (DOR)

    Duration of response was defined as the time from the first tumor assessment when the confirmed CR/PR response criterion was met to the date of disease progression based on investigational assessment following RECIST 1.1.

    Time frame: Up to 241 days

  5. Number of Participants With Adverse Events

    A treatment emergent adverse events (TEAE) was defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. A TESAE is defined as any serious adverse event (SAE) occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. Safety and Severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Lifethreatening; Grade 5-Fatal;

    Time frame: Time of the first dose of study treatment to 28 days after the last dose of study drug; maximum treatment duration was 24 weeks

Other outcomes

  1. Kaplan Meier Estimate of PFS by Investigator Assessment

    PFS was measured as time from the date of first dose to the date of disease progression according to RECIST 1.1 or death from any cause, whichever was earlier.

    Time frame: Up to 241 days

07

Results

Posted Jan 20, 2016

Participant flow

Participants must have been previously treated and must have had radiologically documented measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and disease progression ≤ 2 months after the last delivery of the last standard therapy. They were enrolled by family of oncogenic proteins (RAS) mutation status .

Participant flow — Overall Study
MilestoneRAS Wildtype: Nab®-PaclitaxelRAS Mutated: Nab®-Paclitaxel
Started1823
Safety population1823
Intent to treat population1720
Completed00
Not completed1823
Withdrew: Adverse event12
Withdrew: Progressive disease1720
Withdrew: Death01

Outcome measures

PrimaryProgression Free Survival (PFS) Rate as Measured at Week 8

PFS rate was measured by Investigator Assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 from the start of study treatment to disease progression or death from any cause, whichever occurred first.

Time frame:
At week 8 assessment period; up to 56 days
Reported as:
Number · percentage of participants
Progression Free Survival (PFS) Rate as Measured at Week 8
percentage of participantsRAS Wildtype: Nab®-PaclitaxelRAS Mutated: Nab®-Paclitaxel
Progression Free Survival (PFS) Rate as Measured at Week 820 (4 to 48)20 (4 to 48)
SecondaryPercentage of Participants With Stable Disease for ≥ 8 Weeks, or Complete or Partial Response According to RECIST Version 1.1; Disease Control Rate (DCR)

DCR was defined as the combined incidence of stable disease confirmed CR or PR and stable disease (SD) measured at the Week 8 assessment or later.

Time frame:
At week 8 and later; up to day 241
Reported as:
Number · Percentage of participants
Percentage of Participants With Stable Disease for ≥ 8 Weeks, or Complete or Partial Response According to RECIST Version 1.1; Disease Control Rate (DCR)
Percentage of participantsRAS Wildtype: Nab®-PaclitaxelRAS Mutated: Nab®-Paclitaxel
Percentage of Participants With Stable Disease for ≥ 8 Weeks, or Complete or Partial Response According to RECIST Version 1.1; Disease Control Rate (DCR)18 (4 to 43)15 (3 to 38)
SecondaryOverall Survival

Overall Survival was the time from the first dose of study drug to patient death from any cause.

Time frame:
Up to 241 days

No measurements were reported for this outcome.

SecondaryOverall Response Rate (ORR)

ORR was defined as the combined incidence of Complete Response (CR) and Partial Response (PR), confirmed no less than 4 weeks after the criteria for response were first met based on RECIST 1.1. Tumor responses were assessed every 2 cycles using RECIST 1.1 and defined as: • Complete response-disappearance of all target lesions • Partial response- At least a 30% decrease in the sum of diameters of target lesions from baseline • Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD) • Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.

Time frame:
Up to 241 days
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsRAS Wildtype: Nab®-PaclitaxelRAS Mutated: Nab®-Paclitaxel
Overall Response Rate (ORR)0 (NA to NA)0 (NA to NA)
SecondaryDuration of Response (DOR)

Duration of response was defined as the time from the first tumor assessment when the confirmed CR/PR response criterion was met to the date of disease progression based on investigational assessment following RECIST 1.1.

Time frame:
Up to 241 days

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events

A treatment emergent adverse events (TEAE) was defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. A TESAE is defined as any serious adverse event (SAE) occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. Safety and Severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0; Severity of AEs were graded (including second primary malignancies) as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Lifethreatening; Grade 5-Fatal;

Time frame:
Time of the first dose of study treatment to 28 days after the last dose of study drug; maximum treatment duration was 24 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsRAS Wildtype: Nab®-PaclitaxelRAS Mutated: Nab®-Paclitaxel
Any TEAE1823
≥1 or more related TEAE1721
≥1 TEAE with Grade 3-41218
≥1 treatment related TEAE with Grade 3 or 4912
≥1 or TEAE Grade 3 or higher1218
≥1 treatment related TEAE with Grade 3 or higher912
Any Serious TEAE510
≥1 or more related serious TEAE20
≥1TEAE with Action of Study Drug Withdrawn12
≥1treatment related TEAE WhereStudy Drug Withdrawn10
≥1TEAE with Action of Study Drug Reduced74
≥1 treatment related TEAE Where Study Drug Reduced64
≥1TEAE with study dose Interrupted78
≥1 treatment related TEAE w Study Drug Interrupted66
≥1TEAE with outcome of death01
Other pre-specifiedKaplan Meier Estimate of PFS by Investigator Assessment

PFS was measured as time from the date of first dose to the date of disease progression according to RECIST 1.1 or death from any cause, whichever was earlier.

Time frame:
Up to 241 days
Reported as:
Median · weeks
Kaplan Meier Estimate of PFS by Investigator Assessment
weeksRAS Wildtype: Nab®-PaclitaxelRAS Mutated: Nab®-Paclitaxel
Kaplan Meier Estimate of PFS by Investigator Assessment8.1 (7.71 to 8.57)7.9 (7.57 to 8.00)

Adverse events

Collected over All adverse events were recorded and monitored by the investigator from the time the informed consent was signed to 28 days after the last dose of study treatment or the End of Treatment, whichever was later; maximum treatment duration was 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RAS Wildtype: Nab®-Paclitaxel—5/18 (27.8%)18/18 (100%)
RAS Mutated: Nab®-Paclitaxel—10/23 (43.5%)23/23 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventRAS Wildtype: Nab®-PaclitaxelRAS Mutated: Nab®-Paclitaxel
General physical health deteriorationGeneral disorders0/183/23
SepsisInfections and infestations2/180/23
PyrexiaGeneral disorders0/182/23
NeutropeniaBlood and lymphatic system disorders1/180/23
Cardio-respiratory arrestCardiac disorders1/180/23
Abdominal painGastrointestinal disorders1/180/23
Abdominal abscessInfections and infestations1/180/23
Peripheral motor neuropathyNervous system disorders1/180/23
Peripheral sensory neuropathyNervous system disorders1/180/23
HypotensionVascular disorders1/180/23
Most frequent other events
Showing 10 of 75
Most frequent other events
EventRAS Wildtype: Nab®-PaclitaxelRAS Mutated: Nab®-Paclitaxel
AstheniaGeneral disorders16/1817/23
AlopeciaSkin and subcutaneous tissue disorders11/189/23
NauseaGastrointestinal disorders4/189/23
DiarrhoeaGastrointestinal disorders6/188/23
Decreased appetiteMetabolism and nutrition disorders4/188/23
AnaemiaBlood and lymphatic system disorders6/186/23
StomatitisGastrointestinal disorders6/185/23
ParaesthesiaNervous system disorders6/182/23
DyspnoeaRespiratory, thoracic and mediastinal disorders6/185/23
NeutropeniaBlood and lymphatic system disorders5/186/23

Baseline characteristics

Intent to Treat (ITT) Includes participants who met all eligibility criteria and received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)RAS Wildtype: Nab®-PaclitaxelRAS Mutated: Nab®-PaclitaxelTotal
Mean64.3 ± 12.3461.9 ± 10.5663.0 ± 11.31
Sex: Female, Male
Sex: Female, Male(Participants)RAS Wildtype: Nab®-PaclitaxelRAS Mutated: Nab®-PaclitaxelTotal
Female51015
Male121022
08

Study locations

6 sites
  • Centre Oscar Lambret, Dept. de Cancerologie Digestive et Urologique
    Lille 59, 59020, France
  • Centre Regional de Lutte contre le Cancer Val d'Aurelle
    Montpellier cedex 5, 34298, France
  • CRLCC Centre Rene Gauducheau
    Saint Herblain 44, 44805, France
  • Institut Curie
    Saint-Cloud, 92210, France
  • Centre Alexis Vautrin
    Vandoeuvre-Les-Nancy, 54511, France
  • Institut Gustave Roussy Hematologie
    Villejuif, 94805, France
09

References and documents

Publications

  • Ducreux M, Bennouna J, Adenis A, Conroy T, Lievre A, Portales F, Jeanes J, Li L, Romano A. Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. Cancer Chemother Pharmacol. 2017 Jan;79(1):9-16. doi: 10.1007/s00280-016-3193-5. Epub 2016 Nov 19. PubMed 27866244 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Nov 2014, 6 months.

Results were first posted in Jan 2016, 1 year 2 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 6 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2014
First posted
Apr 3, 2014
StartActual
May 5, 2014
Primary completionActual
Nov 10, 2014
CompletionActual
Jan 9, 2015
Results first posted
Jan 20, 2016
Last update
Apr 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02103062
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 3, 2014
Start date
May 5, 2014
Primary completion
Nov 10, 2014
Completion
Jan 9, 2015
Results posted
Jan 20, 2016
Last update
Apr 21, 2020

Study contacts

Alfredo Romano, MD
study director · Celgene

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion